Dosimetry of [68Ga]-labeled compounds

Applied Radiation and Isotopes

Volumn 76, Issue , 2013, Pages 70-74

  Eberlein, U ^a   Lassmann, M ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Biokinetics; Dosimetry; Ga 68

Indexed keywords

ANIMAL EXPERIMENTS; BIOKINETICS; GA-68; HUMAN DATA; NEUROENDOCRINE TUMORS; PET IMAGES; SOMATOSTATIN RECEPTORS;

DOSIMETRY; IMAGE RESOLUTION;

GALLIUM;

FLUORODEOXYGLUCOSE F 18; GALLIUM 1,47 TRIAZACYCLONONANE 1,47 TRIACETIC ACID GA 68; GALLIUM 68; GALLIUM NODAGA RGDYK GA 68; GALLIUM TETRAXETAN GA 68; GALLIUM TETRAXETAN LANREOTIDE GA 68; GALLIUM TETRAXETAN NAPHTHYLALANIN EOCTREOTIDE GA 68; GALLIUM TETRAXETAN OCTREOTATE GA 68; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN RECEPTOR; TETRAXETAN; UNCLASSIFIED DRUG; 68GA-DOTANOC; 68GA-DOTATATE; GA(III)-DOTATOC; GALLIUM; OCTREOTIDE; ORGANOMETALLIC COMPOUND; 68GA DOTANOC; 68GA DOTATATE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; GA(III) DOTATOC;

ARTICLE; BINDING AFFINITY; DIAGNOSTIC IMAGING; DOSIMETRY; IMAGE QUALITY; ISOTOPE LABELING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; RADIOACTIVITY; RADIODIAGNOSIS; ANALOGS AND DERIVATIVES; HUMAN; NEUROENDOCRINE TUMOR; PROCEDURES; RADIOMETRY; SCINTISCANNING; METHODOLOGY; REVIEW;

GALLIUM RADIOISOTOPES; HUMANS; NEUROENDOCRINE TUMORS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; RADIOMETRY; RADIOPHARMACEUTICALS;

EID: 84878149570     PISSN: 09698043     EISSN: 18729800     Source Type: Journal    
DOI: 10.1016/j.apradiso.2012.06.033     Document Type: Article

References (26)

1. Al-Nahhas A., Win Z., Szyszko T., Singh A., Nanni C., Fanti S., Rubello D. Gallium-68 PET: a new frontier in receptor cancer imaging. Anticancer Res. 2007, 27:4087-4094.
2. Biodistribution and dosimetry of serial PET imaging with Ga-68 labeled F(ab') 2-trastuzumab [WWW Document], 2012. Available from: http://clinicaltrials.gov/ct2/show/NCT00613847.
3. Bolch W.E., Eckerman K.F., Sgouros G., Thomas S.R. MIRD pamphlet no. 21: a generalized schema for radiopharmaceutical dosimetry-standardization of nomenclature. J. Nucl. Med. 2009, 50:477-484.
4. 68Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives. Semin. Nucl. Med. 2011, 41:314-321.
5. 68Ga-NODAGA-RGDyK for αvΒ3 integrin PET imaging. Nuklearmedizin 2011, 50:225-233.
6. 111In-DOTA-Tyr3-octreotide: implications for internal radiotherapy with 90Y-DOTATOC. Eur. J. Nucl. Med. Mol. Imaging 1999, 26:877-886.
7. Eberlein U., Bröer J.H., Vandevoorde C., Santos P., Bardiès M., Bacher K., Nosske D., Lassmann M. Biokinetics and dosimetry of commonly used radiopharmaceuticals in diagnostic nuclear medicine-a review. Eur. J. Nucl. Med. Mol. Imaging 2011, 38:2269-2281.
8. 177Lu-[DOTA0,Tyr3]octreotate therapy in patients with disseminated neuroendocrine tumors: analysis of dosimetry with impact on future therapeutic strategy. Cancer 2010, 116:1084-1092.
9. 68Ga-DOTATOC PET/CT examinations. Nuklearmedizin 2009, 48:201-207.
10. 68Ga-DOTATOC: preliminary data. Eur. J. Nucl. Med. Mol. Imaging 2001, 28:1751-1757.
11. Hudis C.A. Trastuzumab-mechanism of action and use in clinical practice. N. Engl. J. Med. 2007, 357:39-51.
12. IAEA, 2012. Role of internal dosimetry in nuclear medicine. Report of a Consultancy Meeting [WWW Document]. Available from: http://nucleus.iaea.org/HHW/MedicalPhysics/NuclearMedicine/InternalDosimetry/Consultants_report/Report_of_CM_Internal_Dosimetry.pdf.
13. ICRP, 1991. Publication 60: 1990 recommendations of the International Commission on Radiological Protection. Ann ICRP 21 (1-3).
14. ICRP, 2007. Publication 103: the 2007 recommendations of the International Commission of Radiological Protection. Ann ICRP 37 (2-4).
15. ICRP, 2008. Publication 106: radiation dose to patients from radiopharmaceuticals: addendum 3 to ICRP. Publication 53. Ann ICRP 38 (1-2).
16. ICRP, 2009. Publication 110: Adult reference computational phantoms. Ann. ICRP 30 (2).
17. 90Y-DOTATOC therapy. Eur. J. Nucl. Med. Mol. Imaging 2006, 33:1115-1122.
18. Lassmann M., Chiesa C., Flux G., Bardiès M. EANM Dosimetry Committee guidance document: good practice of clinical dosimetry reporting. Eur. J. Nucl. Med. Mol. Imaging 2011, 38:192-200.
19. Lastoria S., D'Ambrosio L., Aurilio M., Caraco' C., Aloj L. Ga-68 DOTATE PET in endocrine tumors: comparison with SRS, dosimetry, clinical impact. J. Nucl. Med. Meet. Abstracts 2009, 50:1713.
20. Martin C.J. Effective dose: how should it be applied to medical exposures?. Br. J. Radiol. 2007, 80:639-647.
21. 68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors. Eur. J. Nucl. Med. Mol. Imaging 2008, 35:72-79.
22. Staaf J., Jacobsson H., Sanchez-Crespo A. A revision of the organ radiation doses from 2-fluoro-2-deoxy-D-glucose with reference to tumour presence. Radiat. Protect. Dosim 2012, 151:43-50.
23. Stabin M.G., Sparks R.B., Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J. Nucl. Med. 2005, 46:1023-1027.
24. 68Ga-DOTA-lanreotide positron emission tomography. Q. J. Nucl. Med. Mol. Imaging 2010, 54:52-60.
25. 68Ga-DOTA-TATE. Eur. J. Nucl. Med. Mol. Imaging 2010, 37:2004-2010.
26. Williams L.E., Liu A., Yamauchi D.M., Lopatin G., Raubitschek A.A., Wong J.Y.C. The two types of correction of absorbed dose estimates for internal emitters. Cancer 2002, 94:1231-1234.